Summary
Boston Scientific Corporation (BSX) reported strong financial results for the second quarter and first half of 2024, demonstrating robust top-line growth and improved profitability. Net sales for the second quarter of 2024 reached $4.12 billion, a 14.5% increase over the prior year, driven by broad-based performance across its segments, particularly Cardiology and MedSurg. For the first half of the year, net sales grew 14.1% to $7.98 billion. The company highlighted significant adoption of its Farapulse™ Pulsed Field Ablation System as a key growth driver. Adjusted net income per diluted share for Q2 2024 was $0.62, a substantial increase from $0.53 in the prior year, reflecting operational efficiencies and strong sales execution. The company also continues to strategically invest in its product pipeline and pursue significant acquisitions, including definitive agreements to acquire Axonics, Inc. and Silk Road Medical, Inc. These results underscore the company's ongoing commitment to innovation and market leadership in the medical device sector, positioning it for continued growth.
Financial Highlights
50 data points| Revenue | $4.12B |
| Cost of Revenue | $1.27B |
| Gross Profit | $2.85B |
| SG&A Expenses | $1.45B |
| Operating Expenses | $2.33B |
| Operating Income | $520.00M |
| Interest Expense | $77.00M |
| Net Income | $322.00M |
| EPS (Basic) | $0.22 |
| EPS (Diluted) | $0.22 |
| Shares Outstanding (Basic) | 1.47B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1Net sales increased by 14.5% to $4.12 billion for the second quarter of 2024 compared to $3.599 billion in the prior year.
- 2First half net sales rose by 14.1% to $7.977 billion, up from $6.988 billion in the prior year.
- 3The Farapulse™ Pulsed Field Ablation System is a significant growth driver, with strong commercial adoption noted.
- 4Reported net income attributable to common stockholders was $324 million ($0.22 per diluted share) for Q2 2024, compared to $261 million ($0.18 per diluted share) in Q2 2023.
- 5Adjusted net income per diluted share for Q2 2024 was $0.62, an increase from $0.53 in Q2 2023.
- 6The company announced definitive agreements to acquire Axonics, Inc. for approximately $3.670 billion and Silk Road Medical, Inc. for approximately $1.260 billion, expected to close in the second half of 2024.
- 7Intangible asset impairment charges were $276 million in Q2 2024, primarily related to acquisitions of Cryterion Medical, Inc. and Devoro Medical, Inc.